Daily administration (i.v.)of 0.06 μg of VS-1 (i.e. a dose equivalent, on a molar basis, to the bioactive dose of full-length CgA) exerted anti-tumor effects similar to those induced by full-length CgA (Figure 6A-6D). This evidence concerns the gene CGA and neoplasm.